|drug2711||QazCovid-in®-vaccine against COVID-19 Wiki||1.00|
|drug2529||Placebo Vaccine Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.20|
|D018352||Coronavirus Infections NIH||0.16|
There is one clinical trial.
Multicenter, randomized, blind, placebo-controlled clinical study of III phases on the assessment of preventive efficiency, safety and immunogenicity QazCovid-in®-vaccine against COVID-19 in healthy adult volunteers
Description: The main objective of the study is to prove the superiority of the QazCovid-in®-vaccine inactivated against COVID-19 in comparison with placebo in terms of seroconversion (the proportion of persons with a fourfold or higher change in antibody titers to SARS-CoV-2)Measure: Terms of seroconversion (the proportion of persons with a fourfold or higher change in antibody titers to SARS-CoV-2) Time: at days 0, 21, 42, 90, 180
Description: The geometric mean titer of serum antibodies ELISA to SARS-CoV-2 after vaccination. The multiplicity of the change in the geometric mean titer of serum antibodies to SARS-CoV-2 after vaccination.Measure: To evaluate the immunogenicity of the QazCovid-in® vaccine inactivated against COVID-19 versus placebo Time: at days 0, 21, 42, 90, 180
Description: The presence of clinical manifestations and a positive laboratory test for SARS-CoV-2 virus RNA within 6 months after vaccinationMeasure: Frequency of confirmed cases of COVID-19 Time: through study completion, an average of 6 months
Description: Determination of the level of production of intracellular cytokines by antigen-activated T-lymphocytesMeasure: Changing of antigen-specific cellular immunity level Time: at days 0, 90, 180
Description: Frequency of adverse reaction in the seven days following each immunization per age groupMeasure: Frequency of adverse events up to seven days after immunization Time: Seven days after each immunization
Description: Frequency of adverse reaction in the 21 days following each immunization per age groupMeasure: Frequency of adverse events up to 21 days after immunization Time: 21 days after each immunization
Description: Incidence of serious adverse events during the studyMeasure: Incidence of serious adverse events during the study Time: throughout the study, an average of 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports